Table 3 Univariate and multivariate analysis of overall survival.

From: Up-regulation of BRCA1-associated RING Domain 1 Promotes Hepatocellular Carcinoma Progression by Targeting Akt Signaling

Clinical character

Category

No.of patients

Univariate analysis

Multivariate analysis

Mean

95% CI

P value

HR (95% CI)

P value

BARD1 expression

Low

63

57.31

49.25–65.36

0.003

1.655 (1.100–2.489)

0.016

High

146

40.33

34.98–45.69

Gender

Female

33

53.26

41.42–65.10

0.164

  

Male

176

43.97

39.03–48.91

Age (years)

≤55

141

44.91

39.35–50.47

0.718

  

>55

68

46.42

38.34–54.49

Family history

No

176

43.70

38.72–48.68

0.133

  

Yes

33

54.63

43.41–65.85

HBsAg

Negative

39

44.44

34.13–54.74

0.866

  

Positive

170

45.63

40.52–50.74

Median size (range, cm)

≤5

73

67.38

61.44–73.31

<0.001

2.160 (1.308–3.568)

0.003

>5

136

33.61

28.30–38.91

Cirrhosis

No

20

42.25

27.93–56.58

0.698

  

Yes

189

45.75

40.91–50.58

Tumor number

Single

141

51.38

45.88–56.88

<0.001

1.151 (0.713–1.857)

0.565

Multiple

68

33.06

25.61–40.50

Wine-drinking

No

103

49.55

42.73–56.37

0.067

  

Yes

106

41.52

35.47–47.57

TNM stage

I–II

91

61.48

55.54–67.43

<0.001

1.980 (1.198–3.272)

0.008

III–IV

118

33.01

27.24–38.79

Metastasis

No

178

46.59

41.59–51.59

0.204

  

Yes

31

38.77

27.63–49.90

BCLC stage

0-A

96

60.16

54.05–66.27

<0.001

1.159 (0.639–2.103)

0.627

B–C

113

32.87

27.11–38.63

AFP (ng/ml)

≤100

84

49.32

42.20–56.44

0.178

  

>100

125

42.79

36.85–48.73

AST (U/L)

≤40

97

58.27

51.78–64.77

<0.001

1.637 (1.052–2.546)

0.029

>40

112

34.29

28.61–39.97

Recurrence

No

135

35.29

29.75–40.84

<0.001

2.736 (1.756–4.264)

<0.001

Yes

74

63.93

57.79–70.67

Back to article page